Skip to main content

Advertisement

Table 8 Differences in the approach to a first line treatment of CSU in physicians who do and do not follow the guidelines

From: Management of chronic spontaneous urticaria: a worldwide perspective

Treatment Compared groups n % (n) of physicians, who follow the guidelines % (n) of physicians, who don’t follow the guidelines X2 p
First-generation H1-antihistamines Administer 173 15.4 (160) 14.8 (13) 0.026 0.873
No 953 84.6 (878) 85.2 (75)
Second-generation H1-antihistamines at standard dose Administer 704 64 (664) 45.5 (40) 11.868 0.001
No 422 36 (374) 54.5 (48)
Updosed second-generation H1-antihistamines Administer 540 47.8 (496) 50.0 (44) 0.160 0.690
No 586 52.2 (542) 50.0 (44)
H2-antihistamines (e.g. famotidine or ranitidine) Administer 224 19.7 (204) 22.7 (20) 0.481 0.488
No 902 80.3 (834) 77.3 (68)
Ciclosporin Administer 15 1.4 (15) 0 1.289 0.256
No 1111 98.6 (1023) 100 (88)
Omalizumab Administer 32 3.0 (31) 1.1 (1) 1.006 0.316
No 1094 97.0 (1007) 98.9 (87)
Montelukast Administer 150 13.2 (137) 14.8 (13) 0.174 0.676
No 976 86.8 (901) 85.2 (75)
Dapsone Administer 7 0.6 (6) 1.1 (1) 0.409 0.522
No 1119 99.4 (1032) 98.9 (87)
Systemic corticosteroids (for less than 10 days) Administer 215 18.7 (194) 23.9 (21) 1.406 0.236
No 911 81.3 (844) 76.1 (67)
Systemic corticosteroids (for more than 10 days in a row) Administer 16 1.5 (16) 0 1.376 0.241
No 1110 98.5 (1022) 100 (88)
Tricyclic antidepressants (e.g. doxepin) Administer 35 3.0 (31) 4.5 (4) 0.655 0.418
No 1091 97.0 (1007) 95.5 (84)
  1. Values marked in bold indicate a statistically significant difference (p < 0.05)